🔎 Trials Near Me

Home › Marginal Zone Lymphoma

Marginal Zone Lymphoma clinical trials recruiting in the U.S.

54 studies for Marginal Zone Lymphoma are recruiting participants at sites across the United States.

Cities with the most studies

By state

Recently updated studies

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07101328

A Study of ARC-02 in B-cell NHL

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07691606

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579

A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas

RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07029217

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04545762

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT07424833

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06796998

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06026319

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05006716

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06350318

Epco, Zanu, Ritux for R/R FL or MZL

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06563596

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05296070

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT04792502

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06792825

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06340737

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

RecruitingPhase 1
Ages 18 to 81 · All sexes · Updated Aug 6, 2026 · NCT05990465

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06708897

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.